Collegium Pharma (COLL) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Collegium Reports Full-Year 2019 Revenue of $296.7 Million
February 27, 2020 4:02 PM EST 2019 Revenue Growth of 6%, Driven by Xtampza ER revenue growth of 51%
Xtampza® ER Prescriptions Grew 49% in 2019
Collegium Guides to Profitability in 2020
Conference Call Scheduled for Today at 4:30 p.m. ET
STOUGHTON, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Â Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to... More
